Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson’s Disease Mice

MLA

Huang Y, et al. “Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson’s Disease Mice.” International Journal of Nanomedicine, vol. ume 19, Oct. 2024, pp. 10401–14. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.36db82c31dfe4bb9a810602e319f90e9&authtype=sso&custid=ns315887.

APA

Huang Y, Wang X, Li W, Yue F, Wang M, & Zhou F. (2024). Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson’s Disease Mice. International Journal of Nanomedicine, ume 19, 10401–10414.

Chicago

Huang Y, Wang X, Li W, Yue F, Wang M, and Zhou F. 2024. “Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson’s Disease Mice.” International Journal of Nanomedicine ume 19 (October): 10401–14. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.36db82c31dfe4bb9a810602e319f90e9&authtype=sso&custid=ns315887.